Abstract
Overview
Introduction
In 2005, around 30,000 renal transplants were conducted in the seven major
markets. In order to prevent the patient's immune system from rejecting the
transplanted organ, daily immunosuppression therapy is a necessity for the
lifetime of the graft with a base maintenance drug (cyclosporine, tacrolimus,
sirolimus) combined with adjunctive therapies (azathioprine, mycophenolate
mofetil, steroids).
Scope
- Historical and recent trends in immunosuppressive therapy including
current clinical practice and clinical advantages and side effects of
treatments
- Organ supply, national donation rates, waiting lists and forecasts of the
number of transplants and maintenance populations to 2015
- Primary diagnosis, graft survival rates, reasons for late graft failure
and risk factors associated with acute rejection
- Future market outlook including calcineurin inhibitor avoidance/withdrawal
strategies
Report Highlights
30,000 renal transplants were performed in 2005, increasing to 43,000 by 2015
(CAGR, 2005-15, 4%), although the "organ gap" may widen further as increasing
morbidity, such as diabetes mellitus, drives demand. The number of patients
with functioning kidney transplants will double to 428,000 by 2015, creating a
large group of patients with unique and complex long-term medical care needs
directly attributable to adverse effects of immunosuppressive drugs, including
nephrotoxicity, diabetes, hypertension, hyperlipidemia and vulnerability to
infection. Although prevention of acute rejection remains a primary treatment
goal, agents that do not impair long-term renal function are required. While
results from sirolimus based calcineurin-inhibitor withdrawal regimens are
inconclusive more promising results are emerging from use in the
calcineurin-inhibitor avoidance or switching setting.
Reasons to Purchase
- Identify changing trends in immunosuppressive protocols
- Understand the most common treatment protocols in renal transplantation by
patient type
- Quantify the future market size based on the number of transplants and
renal maintenance populations
| 
View Cart
